Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuropeptide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Neuropeptide. Displaying page 1 of 1.
    EudraCT Number: 2014-000129-19 Sponsor Protocol Number: NPY Start Date*: 2015-08-28
    Sponsor Name:Karolinska University Hospital, Huddinge
    Full Title: A randomized , double-blind, placebo-controlled study of antidepressant effects of the endogen compound neuropeptide y (NPY) in patients suffering from major depressive disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-006136-29 Sponsor Protocol Number: PDT-sBCC-MP-V1.0 Start Date*: 2006-12-12
    Sponsor Name:Peter Wolf MD, Department of Dermatology, Medical University of Graz
    Full Title: Mikroperfusions-Pilotstudie zur Korrelation von Schmerzreaktion und neurogener Entzündung bei photodynamischer Therapie superfizieller Basaliome (English: Microperfusion-pilotstudy to correlate pa...
    Medical condition: Superficial basal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012218-30 Sponsor Protocol Number: ML22648 Start Date*: 2009-10-06
    Sponsor Name:Roche Farmacêutica Química, Lda.
    Full Title: A randomized, double-blind, placebo-controlled study to assess the efficacy of tocilizumab (TCZ) + non-biological DMARD in reducing synovitis as measured by magnetic resonance imaging (MRI) at 12 w...
    Medical condition: Men and women > 18 years of age with RA who are currently experiencing an inadequate clinical response to a stable dose of non-biologic DMARDs (at least 12 weeks) and with MRI documented synovitis ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023208-29 Sponsor Protocol Number: OXT-003 Start Date*: 2011-08-02
    Sponsor Name:Rheinische Friedrich-Wilhelms-University of Bonn
    Full Title: Effects of Oxytocin on opioide withdrawal symptoms
    Medical condition: Individuals with opioid dependence who are voluntary inpatients from detoxification unit are investigated. The opioid withdrawal symptome are observed.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002342-11 Sponsor Protocol Number: D1449L00033 Start Date*: 2007-04-19
    Sponsor Name:Klinikum Fulda gAG
    Full Title: Multicenter study of neurotransmitters and neuropeptides in schizophrenia: A multidisciplinary study of biological, pharmacokinetic, receptor occupancy and clinical relationships in patients suffer...
    Medical condition: Patients have to fulfill the diagnostic criteria of a schizophrenia according to DSM-IV.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005063-28 Sponsor Protocol Number: Emend2 Start Date*: 2013-10-02
    Sponsor Name:University of Gothenburg
    Full Title: Release of substance P during peritoneal dialysis: effects of intervention. Controlled cross-over study of the neurokinin-1 receptor antagonist Aprepitant
    Medical condition: End stage renal disease under treatment with peritoneal dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001553-32 Sponsor Protocol Number: MR/M024954/1 Start Date*: 2015-10-09
    Sponsor Name:Imperial College, Joint Research Compliance Office
    Full Title: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
    Medical condition: menopausal hot flushes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10027311 Menopause flushing LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006445-41 Sponsor Protocol Number: CTSSTS1010207V2 Start Date*: 2012-01-28
    Sponsor Name:HEALTH RICERCAE SVILUPPO SRL
    Full Title: The irreversibility of hemorrhagic shock treatment with anti-opiod neuropeptide
    Medical condition: Mortality of hemorrhagic shock grade 2 and 3 is from 50 to '80% in the first 24 hours, and morbidity and mortality betrayed is to 7 to 8 days of' 90% for Acute Respiratory Distress Syndrome and / o...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10049771 Shock haemorrhagic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018740-13 Sponsor Protocol Number: acareoxt01 Start Date*: 2011-08-25
    Sponsor Name:University Medical Center Groningen
    Full Title: Short- and long-term effects of oxytocin on empathy and social behaviour in autistic and antisocial male adults.
    Medical condition: Antisocial personality disorder Autism spectrum disorder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002822 Antisocial personality disorder LLT
    12.1 10063844 Autism spectrum disorder LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000091-25 Sponsor Protocol Number: 2014GU001B Start Date*: 2014-09-01
    Sponsor Name:Royal Brompton and Harefield NHS Foundation Trust
    Full Title: A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost (Ventavis®) in patients with Eisenmenger syndrome
    Medical condition: Pulmonary Arterial Hypertension Eisenmenger syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10037405 Pulmonary hypertension primary LLT
    17.0 100000004855 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001547-12 Sponsor Protocol Number: DC2017RACELINES01 Start Date*: 2017-12-21
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000215-32 Sponsor Protocol Number: Pycno2015-14 Start Date*: 2016-10-04
    Sponsor Name:University of Antwerp
    Full Title: Effect of Pycnogenol® on Attention-Deficit Hyperactivity Disorder (ADHD): A randomized, double blind, placebo and active product controlled multicenter trial.
    Medical condition: Attention-deficit hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10003737 Attention deficit/hyperactivity disorder NOS LLT
    19.0 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    19.0 10037175 - Psychiatric disorders 10003735 Attention deficit-hyperactivity disorder LLT
    19.0 10037175 - Psychiatric disorders 10003734 Attention deficit disorder of childhood without mention of hyperactivity LLT
    19.0 10037175 - Psychiatric disorders 10003733 Attention deficit disorder of childhood with hyperactivity LLT
    19.0 10037175 - Psychiatric disorders 10003732 Attention deficit disorder of childhood LLT
    19.0 10037175 - Psychiatric disorders 10003731 Attention deficit disorder LLT
    19.0 100000004852 10003729 Attention concentration difficulty LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 07:02:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA